| 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE | The metabolism of Apomorphine can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE. | Experimental |
| Acebutolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Acebutolol. | Approved |
| Acetazolamide | The risk or severity of adverse effects can be increased when Apomorphine is combined with Acetazolamide. | Approved, Vet Approved |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apomorphine. | Approved |
| Aliskiren | The risk or severity of adverse effects can be increased when Aliskiren is combined with Apomorphine. | Approved, Investigational |
| Alprenolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Alprenolol. | Approved, Withdrawn |
| Amifostine | The risk or severity of adverse effects can be increased when Amifostine is combined with Apomorphine. | Approved, Investigational |
| Amiloride | The risk or severity of adverse effects can be increased when Amiloride is combined with Apomorphine. | Approved |
| Amineptine | Amineptine may decrease the antihypertensive activities of Apomorphine. | Illicit, Withdrawn |
| Amiodarone | Apomorphine may increase the QTc-prolonging activities of Amiodarone. | Approved, Investigational |
| Amisulpride | The therapeutic efficacy of Amisulpride can be decreased when used in combination with Apomorphine. | Approved, Investigational |
| Amitriptyline | Amitriptyline may decrease the antihypertensive activities of Apomorphine. | Approved |
| Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Apomorphine. | Approved |
| Amobarbital | Amobarbital may increase the hypotensive activities of Apomorphine. | Approved, Illicit |
| Amphotericin B | The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine. | Approved, Investigational |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Apomorphine. | Approved |
| Anagrelide | Apomorphine may increase the QTc-prolonging activities of Anagrelide. | Approved |
| Apraclonidine | The risk or severity of adverse effects can be increased when Apraclonidine is combined with Apomorphine. | Approved |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Apomorphine. | Approved, Investigational |
| Arotinolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Arotinolol. | Approved |
| Arsenic trioxide | Apomorphine may increase the QTc-prolonging activities of Arsenic trioxide. | Approved, Investigational |
| Artemether | Apomorphine may increase the QTc-prolonging activities of Artemether. | Approved |
| Asenapine | Apomorphine may increase the QTc-prolonging activities of Asenapine. | Approved |
| Atenolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Atenolol. | Approved |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Apomorphine. | Approved |
| Azithromycin | Apomorphine may increase the QTc-prolonging activities of Azithromycin. | Approved |
| Barbexaclone | Barbexaclone may increase the hypotensive activities of Apomorphine. | Experimental |
| Barbital | Barbital may increase the hypotensive activities of Apomorphine. | Illicit |
| Barnidipine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Barnidipine. | Approved |
| Bedaquiline | Apomorphine may increase the QTc-prolonging activities of Bedaquiline. | Approved |
| Befunolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Befunolol. | Experimental |
| Benazepril | The risk or severity of adverse effects can be increased when Benazepril is combined with Apomorphine. | Approved, Investigational |
| Bendroflumethiazide | The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Apomorphine. | Approved |
| Benmoxin | The metabolism of Apomorphine can be decreased when combined with Benmoxin. | Withdrawn |
| Bepridil | The risk or severity of adverse effects can be increased when Apomorphine is combined with Bepridil. | Approved, Withdrawn |
| Betaxolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Betaxolol. | Approved |
| Bevantolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Bevantolol. | Approved |
| Bisoprolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Bisoprolol. | Approved |
| Blonanserin | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Blonanserin. | Approved |
| Bopindolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Bopindolol. | Approved |
| Bortezomib | The risk or severity of adverse effects can be increased when Apomorphine is combined with Bortezomib. | Approved, Investigational |
| Bretylium | The risk or severity of adverse effects can be increased when Bretylium is combined with Apomorphine. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Brimonidine is combined with Apomorphine. | Approved |
| Bromocriptine | Bromocriptine may increase the vasoconstricting activities of Apomorphine. | Approved, Investigational |
| Bufuralol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Bufuralol. | Experimental, Investigational |
| Bumetanide | The risk or severity of adverse effects can be increased when Bumetanide is combined with Apomorphine. | Approved |
| Bupivacaine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Bupivacaine. | Approved, Investigational |
| Bupranolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Bupranolol. | Approved |
| Bupropion | The risk or severity of adverse effects can be increased when Apomorphine is combined with Bupropion. | Approved |
| Cabergoline | Cabergoline may increase the vasoconstricting activities of Apomorphine. | Approved |
| Canagliflozin | The risk or severity of adverse effects can be increased when Canagliflozin is combined with Apomorphine. | Approved |
| Candesartan | The risk or severity of adverse effects can be increased when Candesartan is combined with Apomorphine. | Approved |
| Captopril | The risk or severity of adverse effects can be increased when Captopril is combined with Apomorphine. | Approved |
| Carbetocin | The risk or severity of adverse effects can be increased when Apomorphine is combined with Carbetocin. | Approved |
| Cariprazine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Cariprazine. | Approved |
| Caroxazone | The metabolism of Apomorphine can be decreased when combined with Caroxazone. | Withdrawn |
| Carteolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Carteolol. | Approved |
| Carvedilol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Carvedilol. | Approved, Investigational |
| Celiprolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Celiprolol. | Approved, Investigational |
| Ceritinib | Apomorphine may increase the QTc-prolonging activities of Ceritinib. | Approved |
| Chloroquine | Apomorphine may increase the QTc-prolonging activities of Chloroquine. | Approved, Vet Approved |
| Chlorothiazide | The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apomorphine. | Approved, Vet Approved |
| Chlorpromazine | The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Apomorphine. | Approved, Vet Approved |
| Chlorprothixene | The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Apomorphine. | Approved, Withdrawn |
| Chlorthalidone | The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Apomorphine. | Approved |
| Cilazapril | The risk or severity of adverse effects can be increased when Cilazapril is combined with Apomorphine. | Approved |
| Cilnidipine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Cilnidipine. | Approved |
| Ciprofloxacin | Apomorphine may increase the QTc-prolonging activities of Ciprofloxacin. | Approved, Investigational |
| Cisapride | Apomorphine may increase the QTc-prolonging activities of Cisapride. | Approved, Investigational, Withdrawn |
| Citalopram | Apomorphine may increase the QTc-prolonging activities of Citalopram. | Approved |
| Clarithromycin | Apomorphine may increase the QTc-prolonging activities of Clarithromycin. | Approved |
| Clevidipine | The risk or severity of adverse effects can be increased when Clevidipine is combined with Apomorphine. | Approved |
| Clofarabine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Clofarabine. | Approved, Investigational |
| Clomipramine | Clomipramine may decrease the antihypertensive activities of Apomorphine. | Approved, Vet Approved |
| Clonidine | The risk or severity of adverse effects can be increased when Clonidine is combined with Apomorphine. | Approved |
| Clozapine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Clozapine. | Approved |
| Conivaptan | The risk or severity of adverse effects can be increased when Apomorphine is combined with Conivaptan. | Approved, Investigational |
| Crizotinib | Apomorphine may increase the QTc-prolonging activities of Crizotinib. | Approved |
| Cyclobenzaprine | Cyclobenzaprine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Dapagliflozin | The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Apomorphine. | Approved |
| Desflurane | The risk or severity of adverse effects can be increased when Apomorphine is combined with Desflurane. | Approved |
| Desipramine | Desipramine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Desvenlafaxine | Desvenlafaxine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Apomorphine. | Approved, Vet Approved |
| Diclofenamide | The risk or severity of adverse effects can be increased when Diclofenamide is combined with Apomorphine. | Approved |
| Dihydroergotamine | Dihydroergotamine may increase the vasoconstricting activities of Apomorphine. | Approved |
| Diltiazem | The risk or severity of adverse effects can be increased when Diltiazem is combined with Apomorphine. | Approved |
| Dinutuximab | The risk or severity of adverse effects can be increased when Dinutuximab is combined with Apomorphine. | Approved |
| Dipyridamole | The risk or severity of adverse effects can be increased when Dipyridamole is combined with Apomorphine. | Approved |
| Disopyramide | Apomorphine may increase the QTc-prolonging activities of Disopyramide. | Approved |
| Dofetilide | Apomorphine may increase the QTc-prolonging activities of Dofetilide. | Approved |
| Dolasetron | Dolasetron may increase the hypotensive activities of Apomorphine. | Approved |
| Domperidone | Apomorphine may increase the QTc-prolonging activities of Domperidone. | Approved, Investigational, Vet Approved |
| Dosulepin | Dosulepin may decrease the antihypertensive activities of Apomorphine. | Approved |
| Doxazosin | The risk or severity of adverse effects can be increased when Doxazosin is combined with Apomorphine. | Approved |
| Doxepin | Doxepin may decrease the antihypertensive activities of Apomorphine. | Approved |
| Dronedarone | Apomorphine may increase the QTc-prolonging activities of Dronedarone. | Approved |
| Droperidol | The therapeutic efficacy of Droperidol can be decreased when used in combination with Apomorphine. | Approved, Vet Approved |
| Droxidopa | Apomorphine may increase the hypertensive activities of Droxidopa. | Approved, Investigational |
| Duloxetine | Apomorphine may increase the orthostatic hypotensive activities of Duloxetine. | Approved |
| Efonidipine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Efonidipine. | Approved |
| Eliglustat | Apomorphine may increase the QTc-prolonging activities of Eliglustat. | Approved |
| Empagliflozin | The risk or severity of adverse effects can be increased when Empagliflozin is combined with Apomorphine. | Approved |
| Enalapril | The risk or severity of adverse effects can be increased when Enalapril is combined with Apomorphine. | Approved, Vet Approved |
| Enalaprilat | The risk or severity of adverse effects can be increased when Apomorphine is combined with Enalaprilat. | Approved |
| Eplerenone | The risk or severity of adverse effects can be increased when Eplerenone is combined with Apomorphine. | Approved |
| Epoprostenol | The risk or severity of adverse effects can be increased when Apomorphine is combined with Epoprostenol. | Approved |
| Eprosartan | The risk or severity of adverse effects can be increased when Eprosartan is combined with Apomorphine. | Approved |
| Ergoloid mesylate | Ergoloid mesylate may increase the vasoconstricting activities of Apomorphine. | Approved |
| Ergonovine | Ergonovine may increase the vasoconstricting activities of Apomorphine. | Approved |
| Ergotamine | Ergotamine may increase the vasoconstricting activities of Apomorphine. | Approved |
| Erythromycin | Apomorphine may increase the QTc-prolonging activities of Erythromycin. | Approved, Vet Approved |
| Escitalopram | Apomorphine may increase the QTc-prolonging activities of Escitalopram. | Approved, Investigational |
| Esmirtazapine | Esmirtazapine may decrease the antihypertensive activities of Apomorphine. | Investigational |
| Esmolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Esmolol. | Approved |
| Etacrynic acid | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Apomorphine. | Approved |
| Felodipine | The risk or severity of adverse effects can be increased when Felodipine is combined with Apomorphine. | Approved, Investigational |
| Fenoldopam | The risk or severity of adverse effects can be increased when Apomorphine is combined with Fenoldopam. | Approved |
| Fimasartan | The risk or severity of adverse effects can be increased when Apomorphine is combined with Fimasartan. | Approved |
| Flecainide | Apomorphine may increase the QTc-prolonging activities of Flecainide. | Approved, Withdrawn |
| Fluoxetine | Apomorphine may increase the QTc-prolonging activities of Fluoxetine. | Approved, Vet Approved |
| Flupentixol | Apomorphine may increase the QTc-prolonging activities of Flupentixol. | Approved, Withdrawn |
| Fluphenazine | The therapeutic efficacy of Fluphenazine can be decreased when used in combination with Apomorphine. | Approved |
| Fosinopril | The risk or severity of adverse effects can be increased when Fosinopril is combined with Apomorphine. | Approved |
| Furazolidone | The metabolism of Apomorphine can be decreased when combined with Furazolidone. | Approved, Vet Approved |
| Furosemide | The risk or severity of adverse effects can be increased when Furosemide is combined with Apomorphine. | Approved, Vet Approved |
| Gadobenic acid | Apomorphine may increase the QTc-prolonging activities of Gadobenic acid. | Approved |
| Gemifloxacin | Apomorphine may increase the QTc-prolonging activities of Gemifloxacin. | Approved, Investigational |
| Goserelin | Apomorphine may increase the QTc-prolonging activities of Goserelin. | Approved |
| Granisetron | Granisetron may increase the hypotensive activities of Apomorphine. | Approved, Investigational |
| Guanfacine | The risk or severity of adverse effects can be increased when Guanfacine is combined with Apomorphine. | Approved, Investigational |
| Haloperidol | The therapeutic efficacy of Haloperidol can be decreased when used in combination with Apomorphine. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Apomorphine is combined with Halothane. | Approved, Vet Approved |
| Hexobarbital | Hexobarbital may increase the hypotensive activities of Apomorphine. | Approved |
| Hydracarbazine | The metabolism of Apomorphine can be decreased when combined with Hydracarbazine. | Approved |
| Hydralazine | The risk or severity of adverse effects can be increased when Hydralazine is combined with Apomorphine. | Approved |
| Hydrochlorothiazide | The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Apomorphine. | Approved, Vet Approved |
| Hydroflumethiazide | The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydroflumethiazide. | Approved |
| Ibutilide | Apomorphine may increase the QTc-prolonging activities of Ibutilide. | Approved |
| Iloperidone | Apomorphine may increase the QTc-prolonging activities of Iloperidone. | Approved |
| Iloprost | The risk or severity of adverse effects can be increased when Apomorphine is combined with Iloprost. | Approved, Investigational |
| Imipramine | Imipramine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Indapamide | The risk or severity of adverse effects can be increased when Indapamide is combined with Apomorphine. | Approved |
| Indenolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Indenolol. | Withdrawn |
| Indoramin | The risk or severity of adverse effects can be increased when Apomorphine is combined with Indoramin. | Withdrawn |
| Iobenguane | The therapeutic efficacy of Iobenguane can be decreased when used in combination with Apomorphine. | Approved |
| Iproclozide | The metabolism of Apomorphine can be decreased when combined with Iproclozide. | Withdrawn |
| Iproniazid | The metabolism of Apomorphine can be decreased when combined with Iproniazid. | Withdrawn |
| Irbesartan | The risk or severity of adverse effects can be increased when Irbesartan is combined with Apomorphine. | Approved, Investigational |
| Isocarboxazid | The metabolism of Apomorphine can be decreased when combined with Isocarboxazid. | Approved |
| Isoflurane | The risk or severity of adverse effects can be increased when Apomorphine is combined with Isoflurane. | Approved, Vet Approved |
| Isosorbide Dinitrate | The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Apomorphine. | Approved |
| Isosorbide Mononitrate | The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Apomorphine. | Approved |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Apomorphine. | Approved, Withdrawn |
| Isradipine | The risk or severity of adverse effects can be increased when Isradipine is combined with Apomorphine. | Approved |
| Labetalol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Labetalol. | Approved |
| Lacidipine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Lacidipine. | Approved |
| Lenvatinib | Apomorphine may increase the QTc-prolonging activities of Lenvatinib. | Approved |
| Lercanidipine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Lercanidipine. | Approved, Investigational |
| Leuprolide | Apomorphine may increase the QTc-prolonging activities of Leuprolide. | Approved, Investigational |
| Levobunolol | The risk or severity of adverse effects can be increased when Levobunolol is combined with Apomorphine. | Approved |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Levobupivacaine. | Approved |
| Levodopa | Apomorphine may increase the orthostatic hypotensive activities of Levodopa. | Approved |
| Levofloxacin | Apomorphine may increase the QTc-prolonging activities of Levofloxacin. | Approved, Investigational |
| Levomilnacipran | Levomilnacipran may decrease the antihypertensive activities of Apomorphine. | Approved |
| Levosimendan | The risk or severity of adverse effects can be increased when Apomorphine is combined with Levosimendan. | Approved, Investigational |
| Lisinopril | The risk or severity of adverse effects can be increased when Lisinopril is combined with Apomorphine. | Approved, Investigational |
| Lofexidine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Lofexidine. | Approved, Investigational |
| Lopinavir | Apomorphine may increase the QTc-prolonging activities of Lopinavir. | Approved |
| Losartan | The risk or severity of adverse effects can be increased when Losartan is combined with Apomorphine. | Approved |
| Loxapine | The therapeutic efficacy of Loxapine can be decreased when used in combination with Apomorphine. | Approved |
| Lumateperone | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lumateperone. | Investigational |
| Lumefantrine | Apomorphine may increase the QTc-prolonging activities of Lumefantrine. | Approved |
| Lurasidone | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone. | Approved |
| Mannitol | The risk or severity of adverse effects can be increased when Mannitol is combined with Apomorphine. | Approved, Investigational |
| Mebanazine | The metabolism of Apomorphine can be decreased when combined with Mebanazine. | Withdrawn |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Apomorphine. | Approved |
| Melperone | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Melperone. | Approved |
| Mesoridazine | The therapeutic efficacy of Mesoridazine can be decreased when used in combination with Apomorphine. | Approved |
| Methadone | Apomorphine may increase the QTc-prolonging activities of Methadone. | Approved |
| Methazolamide | The risk or severity of adverse effects can be increased when Methazolamide is combined with Apomorphine. | Approved |
| Methohexital | Methohexital may increase the hypotensive activities of Apomorphine. | Approved |
| Methotrimeprazine | The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Apomorphine. | Approved |
| Methyclothiazide | The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apomorphine. | Approved |
| Methyldopa | The risk or severity of adverse effects can be increased when Methyldopa is combined with Apomorphine. | Approved |
| Methylene blue | The metabolism of Apomorphine can be decreased when combined with Methylene blue. | Investigational |
| Methylphenidate | The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine. | Approved, Investigational |
| Methylphenobarbital | Methylphenobarbital may increase the hypotensive activities of Apomorphine. | Approved |
| Metipranolol | The risk or severity of adverse effects can be increased when Metipranolol is combined with Apomorphine. | Approved |
| Metoclopramide | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Metoclopramide. | Approved, Investigational |
| Metolazone | The risk or severity of adverse effects can be increased when Metolazone is combined with Apomorphine. | Approved |
| Metoprolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Metoprolol. | Approved, Investigational |
| Mianserin | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Mianserin. | Approved |
| Mifepristone | Mifepristone may increase the QTc-prolonging activities of Apomorphine. | Approved, Investigational |
| Milnacipran | Milnacipran may decrease the antihypertensive activities of Apomorphine. | Approved |
| Minaprine | The metabolism of Apomorphine can be decreased when combined with Minaprine. | Approved |
| Minoxidil | The risk or severity of adverse effects can be increased when Minoxidil is combined with Apomorphine. | Approved |
| Mirtazapine | Mirtazapine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Moclobemide | The metabolism of Apomorphine can be decreased when combined with Moclobemide. | Approved |
| Moexipril | The risk or severity of adverse effects can be increased when Moexipril is combined with Apomorphine. | Approved |
| Molindone | The therapeutic efficacy of Molindone can be decreased when used in combination with Apomorphine. | Approved |
| Morphine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Morphine. | Approved, Investigational |
| Moxifloxacin | Apomorphine may increase the QTc-prolonging activities of Moxifloxacin. | Approved, Investigational |
| Moxonidine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Moxonidine. | Approved |
| Nabilone | The risk or severity of adverse effects can be increased when Apomorphine is combined with Nabilone. | Approved, Investigational |
| Nadolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Nadolol. | Approved |
| Nebivolol | The risk or severity of adverse effects can be increased when Nebivolol is combined with Apomorphine. | Approved, Investigational |
| Nesiritide | The risk or severity of adverse effects can be increased when Nesiritide is combined with Apomorphine. | Approved, Investigational |
| Nialamide | The metabolism of Apomorphine can be decreased when combined with Nialamide. | Withdrawn |
| Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Apomorphine. | Approved |
| Nicorandil | Nicorandil may increase the hypotensive activities of Apomorphine. | Approved |
| Nifedipine | The risk or severity of adverse effects can be increased when Nifedipine is combined with Apomorphine. | Approved |
| Nilotinib | Apomorphine may increase the QTc-prolonging activities of Nilotinib. | Approved, Investigational |
| Nilvadipine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Nilvadipine. | Approved |
| Nimodipine | The risk or severity of adverse effects can be increased when Nimodipine is combined with Apomorphine. | Approved |
| Nisoldipine | The risk or severity of adverse effects can be increased when Nisoldipine is combined with Apomorphine. | Approved |
| Nitrendipine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine. | Approved |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitric Oxide. | Approved |
| Nitroglycerin | The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Apomorphine. | Approved, Investigational |
| Nitroprusside | The risk or severity of adverse effects can be increased when Nitroprusside is combined with Apomorphine. | Approved |
| Nortriptyline | Nortriptyline may decrease the antihypertensive activities of Apomorphine. | Approved |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Apomorphine is combined with Obinutuzumab. | Approved |
| Octamoxin | The metabolism of Apomorphine can be decreased when combined with Octamoxin. | Withdrawn |
| Ofloxacin | Apomorphine may increase the QTc-prolonging activities of Ofloxacin. | Approved |
| Olanzapine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine. | Approved, Investigational |
| Olmesartan | The risk or severity of adverse effects can be increased when Olmesartan is combined with Apomorphine. | Approved, Investigational |
| Ondansetron | Ondansetron may increase the hypotensive activities of Apomorphine. | Approved |
| Oxprenolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Oxprenolol. | Approved |
| Paclitaxel | The risk or severity of adverse effects can be increased when Apomorphine is combined with Paclitaxel. | Approved, Vet Approved |
| Paliperidone | Apomorphine may increase the QTc-prolonging activities of Paliperidone. | Approved |
| Palonosetron | Palonosetron may increase the hypotensive activities of Apomorphine. | Approved, Investigational |
| Panobinostat | Apomorphine may increase the QTc-prolonging activities of Panobinostat. | Approved, Investigational |
| Papaverine | The risk or severity of adverse effects can be increased when Papaverine is combined with Apomorphine. | Approved |
| Pargyline | The metabolism of Apomorphine can be decreased when combined with Pargyline. | Approved |
| Pazopanib | Apomorphine may increase the QTc-prolonging activities of Pazopanib. | Approved |
| Penbutolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Penbutolol. | Approved, Investigational |
| Pentamidine | Apomorphine may increase the QTc-prolonging activities of Pentamidine. | Approved |
| Pentobarbital | Pentobarbital may increase the hypotensive activities of Apomorphine. | Approved, Vet Approved |
| Perflutren | Apomorphine may increase the QTc-prolonging activities of Perflutren. | Approved |
| Perindopril | The risk or severity of adverse effects can be increased when Perindopril is combined with Apomorphine. | Approved |
| Perospirone | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Perospirone. | Approved |
| Perphenazine | The therapeutic efficacy of Perphenazine can be decreased when used in combination with Apomorphine. | Approved |
| Phenelzine | The metabolism of Apomorphine can be decreased when combined with Phenelzine. | Approved |
| Pheniprazine | The metabolism of Apomorphine can be decreased when combined with Pheniprazine. | Withdrawn |
| Phenobarbital | Phenobarbital may increase the hypotensive activities of Apomorphine. | Approved |
| Phenoxybenzamine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenoxybenzamine. | Approved |
| Phenoxypropazine | The metabolism of Apomorphine can be decreased when combined with Phenoxypropazine. | Withdrawn |
| Phentolamine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Phentolamine. | Approved |
| Pimavanserin | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Pimavanserin. | Investigational |
| Pimozide | Apomorphine may increase the QTc-prolonging activities of Pimozide. | Approved |
| Pindolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Pindolol. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Apomorphine is combined with Pipamperone. | Approved |
| Pirlindole | The metabolism of Apomorphine can be decreased when combined with Pirlindole. | Approved |
| Pivhydrazine | The metabolism of Apomorphine can be decreased when combined with Pivhydrazine. | Withdrawn |
| Practolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Practolol. | Approved |
| Pramipexole | The risk or severity of adverse effects can be increased when Apomorphine is combined with Pramipexole. | Approved, Investigational |
| Prazosin | The risk or severity of adverse effects can be increased when Prazosin is combined with Apomorphine. | Approved |
| Primaquine | Apomorphine may increase the QTc-prolonging activities of Primaquine. | Approved |
| Primidone | Primidone may increase the hypotensive activities of Apomorphine. | Approved, Vet Approved |
| Procainamide | Apomorphine may increase the QTc-prolonging activities of Procainamide. | Approved |
| Prochlorperazine | The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Apomorphine. | Approved, Vet Approved |
| Promazine | The therapeutic efficacy of Promazine can be decreased when used in combination with Apomorphine. | Approved, Vet Approved |
| Propafenone | Apomorphine may increase the QTc-prolonging activities of Propafenone. | Approved |
| Propericiazine | The therapeutic efficacy of Propericiazine can be decreased when used in combination with Apomorphine. | Approved |
| Propofol | The risk or severity of adverse effects can be increased when Apomorphine is combined with Propofol. | Approved, Investigational, Vet Approved |
| Propranolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Propranolol. | Approved, Investigational |
| Protriptyline | Protriptyline may decrease the antihypertensive activities of Apomorphine. | Approved |
| Quetiapine | Apomorphine may increase the QTc-prolonging activities of Quetiapine. | Approved |
| Quinapril | The risk or severity of adverse effects can be increased when Quinapril is combined with Apomorphine. | Approved, Investigational |
| Quinidine | Apomorphine may increase the QTc-prolonging activities of Quinidine. | Approved |
| Quinine | Apomorphine may increase the QTc-prolonging activities of Quinine. | Approved |
| Ramipril | The risk or severity of adverse effects can be increased when Ramipril is combined with Apomorphine. | Approved |
| Rasagiline | The metabolism of Apomorphine can be decreased when combined with Rasagiline. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Apomorphine is combined with Remifentanil. | Approved |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Apomorphine. | Approved |
| Riociguat | The risk or severity of adverse effects can be increased when Riociguat is combined with Apomorphine. | Approved |
| Risperidone | Apomorphine may increase the hypotensive activities of Risperidone. | Approved, Investigational |
| Ropinirole | The risk or severity of adverse effects can be increased when Apomorphine is combined with Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Ropivacaine. | Approved |
| Rotigotine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Rotigotine. | Approved |
| RP5063 | The therapeutic efficacy of Apomorphine can be decreased when used in combination with RP5063. | Investigational |
| Sacubitril | The risk or severity of adverse effects can be increased when Apomorphine is combined with Sacubitril. | Approved |
| Safrazine | The metabolism of Apomorphine can be decreased when combined with Safrazine. | Withdrawn |
| Saquinavir | Apomorphine may increase the QTc-prolonging activities of Saquinavir. | Approved, Investigational |
| Secobarbital | Secobarbital may increase the hypotensive activities of Apomorphine. | Approved, Vet Approved |
| Selegiline | The metabolism of Apomorphine can be decreased when combined with Selegiline. | Approved, Investigational, Vet Approved |
| Sertindole | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Sertindole. | Approved, Withdrawn |
| Sevoflurane | The risk or severity of adverse effects can be increased when Apomorphine is combined with Sevoflurane. | Approved, Vet Approved |
| Sodium Nitrite | The risk or severity of adverse effects can be increased when Apomorphine is combined with Sodium Nitrite. | Approved |
| Sotalol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Sotalol. | Approved |
| Spironolactone | The risk or severity of adverse effects can be increased when Spironolactone is combined with Apomorphine. | Approved |
| Streptokinase | The risk or severity of adverse effects can be increased when Apomorphine is combined with Streptokinase. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Apomorphine is combined with Sufentanil. | Approved, Investigational |
| Sulfisoxazole | Apomorphine may increase the QTc-prolonging activities of Sulfisoxazole. | Approved, Vet Approved |
| Tamsulosin | The risk or severity of adverse effects can be increased when Apomorphine is combined with Tamsulosin. | Approved, Investigational |
| Telavancin | Apomorphine may increase the QTc-prolonging activities of Telavancin. | Approved |
| Telithromycin | Apomorphine may increase the QTc-prolonging activities of Telithromycin. | Approved |
| Telmisartan | The risk or severity of adverse effects can be increased when Telmisartan is combined with Apomorphine. | Approved, Investigational |
| Terazosin | The risk or severity of adverse effects can be increased when Terazosin is combined with Apomorphine. | Approved |
| Tetrabenazine | Apomorphine may increase the QTc-prolonging activities of Tetrabenazine. | Approved |
| Thalidomide | The risk or severity of adverse effects can be increased when Apomorphine is combined with Thalidomide. | Approved, Investigational, Withdrawn |
| Thiamylal | Thiamylal may increase the hypotensive activities of Apomorphine. | Approved, Vet Approved |
| Thiopental | Thiopental may increase the hypotensive activities of Apomorphine. | Approved, Vet Approved |
| Thioproperazine | The therapeutic efficacy of Thioproperazine can be decreased when used in combination with Apomorphine. | Approved |
| Thioridazine | Apomorphine may increase the QTc-prolonging activities of Thioridazine. | Withdrawn |
| Thiothixene | The therapeutic efficacy of Thiothixene can be decreased when used in combination with Apomorphine. | Approved |
| Tianeptine | Tianeptine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Timolol | Apomorphine may increase the atrioventricular blocking (AV block) activities of Timolol. | Approved |
| Tizanidine | The serum concentration of Tizanidine can be increased when it is combined with Apomorphine. | Approved |
| Tolazoline | The risk or severity of adverse effects can be increased when Apomorphine is combined with Tolazoline. | Approved, Vet Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Apomorphine is combined with Tolcapone. | Approved, Withdrawn |
| Toloxatone | The metabolism of Apomorphine can be decreased when combined with Toloxatone. | Approved |
| Torasemide | The risk or severity of adverse effects can be increased when Torasemide is combined with Apomorphine. | Approved |
| Toremifene | Apomorphine may increase the QTc-prolonging activities of Toremifene. | Approved, Investigational |
| Trandolapril | The risk or severity of adverse effects can be increased when Trandolapril is combined with Apomorphine. | Approved |
| Trans-2-Phenylcyclopropylamine | The metabolism of Apomorphine can be decreased when combined with Trans-2-Phenylcyclopropylamine. | Experimental |
| Tranylcypromine | The metabolism of Apomorphine can be decreased when combined with Tranylcypromine. | Approved |
| Tretinoin | The risk or severity of adverse effects can be increased when Apomorphine is combined with Tretinoin. | Approved, Investigational, Nutraceutical |
| Triamterene | The risk or severity of adverse effects can be increased when Triamterene is combined with Apomorphine. | Approved |
| Trifluoperazine | The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Apomorphine. | Approved |
| Trimipramine | Trimipramine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Tropisetron | Tropisetron may increase the hypotensive activities of Apomorphine. | Approved, Investigational |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Apomorphine. | Approved, Investigational |
| Vandetanib | Apomorphine may increase the QTc-prolonging activities of Vandetanib. | Approved |
| Vemurafenib | Apomorphine may increase the QTc-prolonging activities of Vemurafenib. | Approved |
| Venlafaxine | Venlafaxine may decrease the antihypertensive activities of Apomorphine. | Approved |
| Verapamil | The risk or severity of adverse effects can be increased when Verapamil is combined with Apomorphine. | Approved |
| Ziprasidone | Apomorphine may increase the QTc-prolonging activities of Ziprasidone. | Approved |
| Zotepine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Zotepine. | Approved |
| Zuclopenthixol | Apomorphine may increase the QTc-prolonging activities of Zuclopenthixol. | Approved, Investigational |
